You are here

  • Home
  • Archive
  • Volume 78, Issue 10
  • Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan

Article metrics

Article menu

Download PDFPDF

Rheumatoid arthritis
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan

 

Online download statistics by month:

Online download statistics by month: July 2019 to September 2024

AbstractFullPdf
Jul 2019446442139
Aug 2019732756263
Sep 2019871868218
Oct 2019498480202
Nov 201923222487
Dec 201922221179
Jan 202018217568
Feb 202014714480
Mar 202012812074
Apr 202010694127
May 2020109108142
Jun 202010210068
Jul 2020847976
Aug 202014113984
Sep 202014413373
Oct 20201029858
Nov 2020847538
Dec 2020968543
Jan 2021746453
Feb 2021968968
Mar 20211059869
Apr 2021665650
May 20211019732
Jun 2021828045
Jul 20211209882
Aug 2021696338
Sep 202112512340
Oct 202110610047
Nov 20211039946
Dec 202111010034
Jan 2022876830
Feb 2022999852
Mar 202211610242
Apr 202210811345
May 2022716832
Jun 2022787231
Jul 2022716727
Aug 2022948838
Sep 202214814740
Oct 20221049843
Nov 2022787636
Dec 2022716739
Jan 20231009045
Feb 2023988735
Mar 2023847636
Apr 2023816931
May 2023848028
Jun 2023999529
Jul 2023686618
Aug 2023907932
Sep 2023595335
Oct 202314714636
Nov 202329028828
Dec 202313812529
Jan 2024797630
Feb 2024686132
Mar 2024848257
Apr 2024696732
May 202411611029
Jun 2024746832
Jul 2024928224
Aug 2024766836
Sep 20249894164
Total880284243796